Michael Thase, MD
In this video series, Michael Thase, MD, professor of psychiatry and director of the mood and anxiety section at Penn Medicine, talked about:
- exciting developments in major depressive disorder treatment, including:
- FDA-approved options: esketamine (Spravato, Janssen), brexanolone (Zulresso, Sage Therapeutics) and Auvelity (dextromethorphan-bupropion, Axome Therapeutics); and
- therapies showing potential: zuranolone (SAGE-217/BIIB125; Biogen, Sage Therapeutics), esmethadone (REL-1017, Relmada Therapetuics) and psilocybin;
- approaching treatment-resistant depression;
- his view on the relationship between stigma and depression;
- access to care and other important areas of unmet need in MDD; and
- the role of mental health apps to help "improve and facilitate care."